UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2018
Commission File Number:001-38547
Autolus Therapeutics plc
(Translation of registrant’s name into English)
Forest House
58 Wood Lane
White City
London W12 7RZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Other Events
ASH Press Releases
On December 2, 2018, Autolus Therapeutics plc (the “Company”) issued a press release providing updated results from two of its ongoing Phase 1/2 clinical trials of AUTO3 inB-cell malignancies which were presented at the 60th American Society of Hematology (“ASH”) Annual Meeting in San Diego, California. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
Additionally, on December 1, 2018, the Company issued a press release announcing the dosing of the first patient in its Phase 1/2 clinical trial of AUTO4 in TRBC1-positive peripheral T cell lymphoma and the presentation of additional data from its preclinical study of AUTO5 targeting TRBC2-positive lymphoma at the 60th ASH Annual Meeting. The press release is attached as Exhibit 99.2 hereto and is incorporated by reference herein.
Information in the attached Exhibits 99.1 and 99.2 is being furnished and these exhibits shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Autolus Therapeutics plc | ||||||
| Date: December 3, 2018 | By: | /s/ Christian Itin | ||||
| Name | Christian Itin, Ph.D. | |||||
| Title: | Chief Executive Officer | |||||
